Narrative reviewcited by the Tayebat archivefull text checked A-CHM-14 in-depth review
Testicular cancer survivors face late effects but almost all survive
Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.
Overview
Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
10-year relative survival is 95%; heart disease and second cancers are the main serious late effects.
Does the study support the specific claim? Partly · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Review late effects.
- How was the study done?
Narrative review.
- What was actually found?
Multiple late effects.
- What do the results mean in everyday life?
Long-term check-ups and healthy lifestyle.
- What are the study's limitations?
Narrative review without systematic search or quality appraisal; much evidence from older treatment eras.
- What does it say about Elawady's specific claim?
Mixed.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Quantitative risks.
Scientific in-depth review
1. Full reference
- Authors
- Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB
- Journal
- Adv Urol
- Year
- 2018
- Identifier
- PMID 29670654 DOI 10.1155/2018/8671832 · PMC5835297
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Conflicts of interest: authors declare none. Funding not stated in the full text (PubMed lists NCI NIH HHS grants).
2. Research question
Late toxicities in long-term testicular-cancer survivors.
3. Study design and population
- Study design
- Narrative review – Narrative clinical review (no systematic search, selection or appraisal methods reported); includes tables adapted from earlier publications
- Population
Long-term testicular cancer survivors (TCS), disease-free >=5 years after primary treatment with cisplatin-based chemotherapy and/or radiotherapy; single-dose carboplatin and 1-2 cycles of BEP for stage I disease explicitly not reviewed
- Country
not applicable
- Period
not applicable
- Sample size
not applicable
- Inclusion and exclusion criteria
not applicable
4. Methods and endpoints
- Exposure / intervention
Cisplatin chemotherapy, radiotherapy
- Comparator
not applicable
- Endpoints
Cardiovascular disease and Raynaud phenomenon, second malignant neoplasms, neurotoxicity, ototoxicity, pulmonary toxicity, nephrotoxicity, hypogonadism, infertility, avascular necrosis, cognitive impairment, anxiety/depression, fatigue, cumulative adverse health outcomes
- Statistical methods
none
5. Actual results
- Results
Summarises cited studies: 10-year relative survival approaching 95%. CVD: RR 1.4-7.1 vs general population or surveillance (e.g. BEP: CAD HR 5.7, 95% CI 1.9-17.1 vs surgery only); in a population-based study of 15,006 TCS (1980-2010) excess CVD mortality was confined to the first year after chemotherapy (HR 4.86, 1.25-32) and not seen thereafter. Second cancers: RR about 1.4-1.9 after radiotherapy; 1.4-fold after modern chemotherapy (SEER, >12,000 TCS); cisplatin-related leukaemia 3.2-fold but only 16 excess cases per 10,000 patients after 15 years. Ototoxicity: 20% symptomatic (Bokemeyer); 18% severe-to-profound hearing loss among 488 North American TCS; each 100 mg/m2 cumulative cisplatin = 3.2 dB worse hearing threshold (4-12 kHz); no effective preventive or therapeutic agent. Peripheral neuropathy in about 20-40%; Raynaud 25-61%; fatal bleomycin pulmonary toxicity about 1-3%; avascular necrosis about 1-2%. Among 952 cisplatin-treated survivors (median age 37): hearing impairment 31.5%, neuropathy 27.0%, CVD 1.5%; about 60% rated health excellent/very good; paternity after 2/3/4 cycles 100%/83%/76%.
- Absolute risks
Reported only as cited prevalences/excess rates from primary studies, e.g. 16 excess leukaemia cases per 10,000 cisplatin-treated patients after 15 years; 5-year cumulative leukaemia incidence about 0.5% (etoposide <2000 mg/m2) vs 2.0% (>=2000 mg/m2); 15-year risk of contralateral testicular cancer 1.9%; CVD 1.5% in 952 survivors at median age 37.
- Authors' conclusion
TCS are an ideal cohort for adult-onset survivorship research; lifelong follow-up, genetic research and risk-based care are needed; in the interim providers should manage cardiovascular risk factors per national guidelines, promote smoking cessation, balanced diet and exercise, and follow general-population cancer screening.
6. Strengths
- Written by leading survivorship researchers; broad coverage of late effects
- Cites large population-based and cohort studies with effect sizes and dose-response
- Explicitly reports favourable context (95% survival, modest absolute excess for leukaemia, no excess CVD mortality beyond year 1 in modern era)
7. Weaknesses
- Narrative review; no systematic search, eligibility criteria or risk-of-bias appraisal
- Selection of cited studies not reproducible; overlapping registry cohorts in SMN table (authors note overlap)
- Many cited data from older treatment eras (pre-1990s)
- Absolute risks only sporadically reported
- Funding not stated in full text
8. Risk of bias
- Orienting tool
- none (narrative review; AMSTAR 2/ROBIS not applicable)
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- high
- Rationale
Overall reflects the absence of systematic methods (risk of selective evidence), not an assessment of the cited primary data, which are largely high-quality cohorts. Changed from 'not_assessable' to a structured judgement. Single-reviewer structured judgement from the full text; a formal assessment requires two independent reviewers and a protocol.
| Domain | Judgement | Rationale |
|---|---|---|
| Search and selection of evidence | high | No search strategy, databases, dates or inclusion criteria reported; selection by the authors. |
| Appraisal of primary studies | high | No risk-of-bias assessment of cited studies; observational associations presented without formal appraisal. |
| Synthesis | some concerns | Narrative; overlapping registry populations noted in table footnote; no pooling. |
| Balance of reporting | low | Benefits and reassuring findings (high survival, small absolute excess, null studies on cognition and SMN after chemotherapy) are reported alongside harms. |
Full-text review (25 October 2026): Added quantitative late-effect data from the review (ototoxicity 3.2 dB per 100 mg/m2, 18% severe-profound; excess CVD mortality only in first year after chemotherapy; 16/10,000 excess leukaemia; 952-survivor AHO prevalences), scope exclusions, COI statement (funding not stated). Bias changed from not_assessable to a structured judgement (high, due to absent systematic methods).
9. Assessment of the statistical interpretation
Relative risks for CVD and second cancers are moderate (1.4-2-fold for most outcomes), with small absolute excesses where reported (e.g. 16/10,000 leukaemia). Ototoxicity is the clearest dose-dependent, frequent and permanent late effect (3.2 dB per 100 mg/m2 cisplatin; 18% severe-to-profound). Effect sizes are taken from heterogeneous primary studies and not pooled.
10. Relevance to the specific claim
Lists late effects; contains a major benefit figure.
11. Independent contrary findings
Itself (95% 10-year survival).
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Appropriate source for the spectrum of late effects in curable testicular cancer, including dose-dependent permanent ototoxicity; it also documents 95% 10-year survival and small absolute excesses, which the archive omits. Narrative review without systematic methods.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | high |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | unknown |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | essentially correct but incomplete |
14. Open questions
Late effects after modern reduced regimens (BEP x3, EP x4, single-dose carboplatin); lifelong CVD and SMN risk as survivors age; genetic predictors of ototoxicity.
15. Linked fact checks
- Cisplatin chemotherapy causes permanent, dose-dependent hearing loss and tinnitus. – Studies supporting the claim
- The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits. – Studies contradicting or limiting the claim
- Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'. – Studies contradicting or limiting the claim
- Cancer cells resist chemotherapy because of their fibrotic interstitial (stromal) environment; fibrosis strangles cells, which then turn cancerous and resist chemo and radiation. – Studies contradicting or limiting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in bibliography (cisplatin/radiotherapy late toxicities).
- A. What was actually studied?
Review of late effects.
- B. What did the authors find?
Range of late effects; survival 95% at 10 years.
- C. What conclusions do the authors themselves draw?
Risk-based follow-up and healthy lifestyle.
- D. What does the archive derive from it?
Late toxicities.
- E. Is this derivation scientifically justified?
Yes for the toxicities (e.g. ototoxicity is dose-dependent, frequent and without effective prevention). The same review states 10-year relative survival of about 95%, that excess cardiovascular mortality after modern chemotherapy was confined to the first year, and that the absolute excess of cisplatin-related leukaemia was 16 per 10,000; the archive mentions none of this.
- Adequacy of the interpretation (by the archive)
- essentially correct but incomplete